Barclays’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.79M | Sell |
34,261
-42,592
| -55% | -$7.36M | ﹤0.01% | 1726 |
|
|
2025
Q4 | $14M | Buy |
76,853
+4,786
| +7% | +$668K | ﹤0.01% | 1450 |
|
|
2025
Q3 | $8.75M | Sell |
72,067
-25,423
| -26% | -$2.86M | ﹤0.01% | 1767 |
|
|
2025
Q2 | $10.2M | Buy |
97,490
+45,620
| +88% | +$4.83M | ﹤0.01% | 1571 |
|
|
2025
Q1 | $6.05M | Sell |
51,870
-46,118
| -47% | -$5.25M | ﹤0.01% | 1760 |
|
|
2024
Q4 | $8.29M | Buy |
97,988
+36,203
| +59% | +$3.33M | ﹤0.01% | 1719 |
|
|
2024
Q3 | $5.55M | Buy |
61,785
+45,509
| +280% | +$3.97M | ﹤0.01% | 2000 |
|
|
2024
Q2 | $1.31M | Sell |
16,276
-203,822
| -93% | -$15.1M | ﹤0.01% | 2430 |
|
|
2024
Q1 | $17.6M | Buy |
220,098
+28,236
| +15% | +$2.37M | 0.01% | 1057 |
|
|
2023
Q4 | $15.3M | Buy |
191,862
+175,052
| +1,041% | +$11.7M | 0.01% | 1209 |
|
|
2023
Q3 | $1.17M | Buy |
16,810
+16,737
| +22,927% | +$1.25M | ﹤0.01% | 2212 |
|
|
2023
Q2 | $5.25K | Buy |
+73
| New | +$5.38K | ﹤0.01% | 4271 |
|
|
2022
Q4 | – | Sell |
-26,572
| Closed | -$1.19M | – | 5266 |
|
|
2022
Q3 | $1.19M | Buy |
+26,572
| New | +$1.33M | ﹤0.01% | 2109 |
|
|
2021
Q4 | – | Sell |
-1,571
| Closed | -$52K | – | 4128 |
|
|
2021
Q3 | $52K | Sell |
1,571
-52,146
| -97% | -$2.03M | ﹤0.01% | 4096 |
|
|
2021
Q2 | $3.62M | Buy |
53,717
+18,681
| +53% | +$1.12M | ﹤0.01% | 1792 |
|
|
2021
Q1 | $1.98M | Buy |
35,036
+23,604
| +206% | +$1.66M | ﹤0.01% | 2282 |
|
|
2020
Q4 | $931K | Hold |
11,432
| – | – | ﹤0.01% | 2804 |
|
|
2020
Q3 | $815K | Sell |
11,432
-6,361
| -36% | -$496K | ﹤0.01% | 2863 |
|
|
2020
Q2 | $1.46M | Sell |
17,793
-16,678
| -48% | -$1.28M | ﹤0.01% | 2412 |
|
|
2020
Q1 | $2.03M | Sell |
34,471
-30,967
| -47% | -$2.52M | ﹤0.01% | 2267 |
|
|
2019
Q4 | $6.76M | Buy |
65,438
+55,438
| +554% | +$2.24M | ﹤0.01% | 1724 |
|
|
2019
Q3 | $202K | Sell |
10,000
-35,660
| -78% | -$916K | ﹤0.01% | 4957 |
|
|
2019
Q2 | $1.18M | Buy |
45,660
+45,485
| +25,991% | +$912K | ﹤0.01% | 3516 |
|
|
2019
Q1 | $2K | Sell |
175
-10,325
| -98% | -$95.9K | ﹤0.01% | 6838 |
|
|
2018
Q4 | $30K | Buy |
+10,500
| New | +$34.5K | ﹤0.01% | 5726 |
|
|
2018
Q3 | – | Sell |
-36,500
| Closed | -$117K | – | 7111 |
|
|
2018
Q2 | $117K | Buy |
36,500
+900
| +3% | +$2.79K | ﹤0.01% | 5130 |
|
|
2018
Q1 | $87K | Buy |
+35,600
| New | +$107K | ﹤0.01% | 5478 |
|
|
2017
Q4 | – | Sell |
-17,500
| Closed | -$97K | – | 6916 |
|
|
2017
Q3 | $97K | Buy |
17,500
+1,310
| +8% | +$7.03K | ﹤0.01% | 4960 |
|
|
2017
Q2 | $89K | Buy |
16,190
+8,333
| +106% | +$34.9K | ﹤0.01% | 4989 |
|
|
2017
Q1 | $30K | Buy |
7,857
+7,718
| +5,553% | +$36.9K | ﹤0.01% | 5605 |
|
|
2016
Q4 | $1K | Hold |
139
| – | – | ﹤0.01% | 6438 |
|
|
2016
Q3 | $1K | Buy |
+139
| New | +$1.05K | ﹤0.01% | 6365 |
|
Other funds holding AXSM
VPM
VCM
DTC
Barclays's AXSM Position: Q1 2026 in Review
Barclays reduced its Axsome Therapeutics (AXSM) stake by 55% in Q1 2026, selling an estimated $7.36M and leaving 34,261 shares worth $5.79M. The position accounts for ﹤0.01% of the portfolio, ranked #1726.
Barclays first reported a position in AXSM in Q3 2016 and has held it in 32 quarters since. The position peaked at $17.6M in Q1 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.
- Barclays held 34,261 shares of Axsome Therapeutics worth $5.79M as of Q1 2026.
- Barclays sold 42,592 Axsome Therapeutics shares in Q1 2026, an estimated $7.36M.
- Axsome Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1726 holding.
- Barclays first reported a position in Axsome Therapeutics in Q3 2016 and has held it in 32 quarters since.
- Barclays's Axsome Therapeutics position peaked at $17.6M in Q1 2024.
- 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.